Aridis Pharmaceuticals Inc. (ARDS)

NASDAQ: ARDS · IEX Real-Time Price · USD
0.930
+0.030 (3.33%)
Sep 30, 2022 4:00 PM EDT - Market closed
3.33%
Market Cap 16.46M
Revenue (ttm) 2.98M
Net Income (ttm) -48.70M
Shares Out 17.70M
EPS (ttm) -3.26
PE Ratio n/a
Forward PE 2.06
Dividend n/a
Ex-Dividend Date n/a
Volume 121,403
Open 0.900
Previous Close 0.900
Day's Range 0.886 - 0.950
52-Week Range 0.680 - 4.340
Beta 1.25
Analysts Buy
Price Target 12.24 (+1,216.1%)
Earnings Date Nov 8, 2022

About ARDS

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caus... [Read more...]

Industry Biotechnology
IPO Date Aug 10, 2018
Employees 34
Stock Exchange NASDAQ
Ticker Symbol ARDS
Full Company Profile

Financial Performance

In 2021, ARDS's revenue was $1.54 million, an increase of 53.50% compared to the previous year's $1,000,000. Losses were -$42.19 million, 88.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ARDS stock is "Buy." The 12-month stock price forecast is 12.24, which is an increase of 1,216.13% from the latest price.

Price Target
$12.24
(1,216.13% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock

LOS GATOS, Calif. , Sept. 27, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to ...

4 days ago - PRNewsWire

Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock

LOS GATOS, Calif. , Sept. 26, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to ...

5 days ago - PRNewsWire

Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update

Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif. , Aug. 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the ...

1 month ago - PRNewsWire

Aridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primates

AR-701 is effective in vitro against SARS-CoV-2 Omicron subvariants, including BA.4 and BA.5 LOS GATOS, Calif. , Aug. 10, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceu...

1 month ago - PRNewsWire

Here's Why Aridis Pharmaceuticals (ARDS) Looks Ripe for Bottom Fishing

Aridis Pharmaceuticals (ARDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

3 months ago - Zacks Investment Research

RedChip Interviews Aridis Pharmaceuticals' CEO Vu Truong

ORLANDO, FL / ACCESSWIRE / June 30, 2022 / RedChip Companies will air a new C-Level interview with Aridis Pharmaceuticals (NASDAQ:ARDS) on The RedChip Money Report® on Bloomberg TV, this Saturday, July ...

3 months ago - Accesswire

Aridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7

LOS GATOS, Calif. , June 3, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

3 months ago - PRNewsWire

Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of 13.73% and 40.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update

Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif. , May 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the d...

4 months ago - PRNewsWire

Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update

Awarded funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 LOS GATOS, Calif. , Marc...

6 months ago - PRNewsWire

Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study

Aridis Pharmaceuticals Inc's (NASDAQ: ARDS) fully human monoclonal antibodies (mAbs) in the AR-701 cocktail has been shown to neutralize the SARS-CoV-2 omicron variant.  Both mAbs conferred complete pro...

7 months ago - Benzinga

Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals

LOS GATOS, Calif., Feb. 17, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

7 months ago - PRNewsWire

Short Squeeze Stocks: ARDS, BBIG and 3 Others Experts Think Are Ready to Pop

As far as short squeeze stocks go, these five companies top the list in terms of both short interest and borrow fee rates right now. The post Short Squeeze Stocks: ARDS, BBIG and 3 Others Experts Think ...

Other symbols: BBIGINDOBLNKEVGO
7 months ago - InvestorPlace

5 Short Squeeze Candidate To Watch: Aridis Pharmaceuticals Tops List, EVgo, Indonesia Energy Corp And More

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Other symbols: EVGOBBIGBLNKINDO
7 months ago - Benzinga

Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 T...

LOS GATOS, Calif., Jan. 27, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

8 months ago - PRNewsWire

Aridis Pharmaceuticals CEO Discusses Monoclonal Antibody Cocktail Protection Against COVID-19 Omicron Variant and Oth...

LOS GATOS, Calif., Dec. 21, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

9 months ago - PRNewsWire

ARDS Stock Alert: The Covid-19 News Sending Aridis Skyrocketing Today

Aridis Pharmaceuticals has a new cocktail, and it may be the ticket out of the omicron variant. Here's why ARDS stock is worth watching.

9 months ago - InvestorPlace

Aridis Stock Rallies After Positive Preclinical Data For COVID-19 Antibody Against Omicron

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) stock is surging after announcing encouraging preclinical data for pan coronavirus fully human monoclonal antibody (mAb) cocktail AR-701. The data show that the...

9 months ago - Benzinga

Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against th...

LOS GATOS, Calif., Dec. 21, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

9 months ago - PRNewsWire

New Strong Sell Stocks for November 15th

ARDS, CNNE, EXK, GP, and IFF have been added to the Zacks Rank #5 (Strong Sell) List on November 15, 2021.

Other symbols: CNNEEXKGPIFF
10 months ago - Zacks Investment Research

Aridis Pharmaceuticals Announces Third Quarter 2021 Results

LOS GATOS, Calif., Nov. 10, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

10 months ago - PRNewsWire

ARIDIS PHARMACT (ARDS) Reports Q2 Loss, Misses Revenue Estimates

ARIDIS PHARMACT (ARDS) delivered earnings and revenue surprises of 3.51% and -91.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Aridis Pharmaceuticals Announces Second Quarter 2021 Results

LOS GATOS, Calif., Aug. 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

1 year ago - PRNewsWire

Analysts Estimate ARIDIS PHARMACT (ARDS) to Report a Decline in Earnings: What to Look Out for

ARIDIS PHARMACT (ARDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research